Abstract
This case introduces Conmana, an anti- pulmonary carcinoma drug developed by Hangzhou Betta Pharmaceuticals, and discusses its market entry experience under the background of upset innovative drug R&D in China. The case describes how Conmana received its market approval; entered pilot hospitals; obtained doctors’ recognition and then further entered over 10 provincial bidding directories and the procurement catalogs of 250 public medical institutes, and finally got coverage on provincial and country medial insurance lists to enable wider access by Chinese patients.
This case aims to help students explore the challenges and opportunities confronted by the current Chinese innovative drug industry by illustrating the journey of Conmana.
| Translated title of the contribution | Conmana: The Odyssey of a New Pharmaceutical in China |
|---|---|
| Original language | Chinese (Simplified) |
| Number of pages | 16 |
| Publication status | Published - 30 Jun 2019 |
Case number
STR-19-593Case normative number
STR-19-593-CCCase type
Field CaseUpdate date
05/08/2021Supplement
For more details, please visit www.chinacases.orgPublished by
China Europe International Business SchoolKeywords
- innovative drugs
- new drug research and development
- new drug market entry
- new drug accessibility
- Chinese medicine
Case studies discipline
- Operations & Management Science
- Strategy
- Others
Case studies industry
- Health Care Services
- Professional, Scientific, and Technical Services
- Utilities